Senior Controls Engineer
About the job
- A bachelor's degree is required; Electrical Engineering is preferred.
- At least five years of professional experience in a controls-related position is required. A master's degree and internship experience may be considered.
- Demonstrated experience in process improvement, scrap reduction, and cost of goods sold reduction is required; high-volume manufacturing experience is preferred.
- Working knowledge of machine design and electrical and mechanical troubleshooting is required.
- Knowledge of Six Sigma and Lean methods is preferred.
- Lead medium- to large-scale manufacturing projects, managing scope, timelines, and budgets in partnership with cross-functional teams.
- Ensure production processes and product designs deliver consistent, high-quality output at optimal cost.
- Drive continuous improvement initiatives focused on quality, overall equipment effectiveness, and assembly methods, ensuring measurable and sustained results.
- Develop and implement automation changes to manufacturing processes, support new equipment introductions, and drive design for manufacturability.
- Conduct and lead root cause analysis efforts for manufacturing issues.
- Serve as an escalation path for troubleshooting and repair of industrial automation equipment.
- Maintain a hands-on presence on the manufacturing floor and partner with operators and maintenance to drive performance and reliability.
- Lead projects involving Lean/Six Sigma initiatives, cost improvement projects, 5S, and Kaizen events.
- Electrical Engineering degree.
- Experience in high-volume manufacturing.
- Knowledge of Six Sigma and Lean methods.
About the company
Haemonetics develops and sells medical technology solutions focused on improving plasma collection and critical-care operations in hospitals and plasma centers. Its products include devices and services that raise plasma yield, increase staff productivity, and enhance the donor experience, enabling healthcare providers to collect plasma more efficiently while maintaining patient care quality. The company generates revenue from one-time equipment sales and recurring service contracts and consumables used with its devices. It differentiates itself by targeting operational efficiency and patient outcomes in high-stakes settings, combining hardware, software, and services to streamline plasma collection and related processes. Haemonetics’ goal is to advance patient care by delivering reliable medical technologies that improve clinical performance and economic outcomes, while maintaining a strong focus on corporate responsibility.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Boston, Massachusetts
Founded
1971
Get referred to Haemonetics
See people who can refer or advise you
Simplify's Take
What believers are saying
- Fiscal 2027 guidance calls for 4%-7% revenue growth and 50-100 basis-point margin expansion.
- Q4 fiscal 2026 revenue rose 4.8%, with organic ex-CSL growth at 8.6%.
- Martin Madaus joined the board July 24, 2026, adding diagnostics and turnaround experience.
What critics are saying
- Blood Center guidance still calls for a mid-single-digit decline in fiscal 2027.
- Haemonetics sued Terumo BCT and Fresenius Kabi in 2026 over plasma patents.
- A plasma share loss to Terumo BCT would gut Haemonetics core franchise.
What makes Haemonetics unique
- Persona PLUS and NexSys PCS target donor-specific plasma yields, reinforcing switching costs.
- VASCADE MVP XL and PerQseal Elite extend Haemonetics across vascular closure.
- Vivasure acquisition adds proprietary closure assets and broadens hospital cross-sell.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Company Match
Employee Stock Purchase Plan
Paid Vacation
Paid Sick Leave
Paid Holidays
Parental Leave
Disability Insurance
Tuition Reimbursement
Growth & Insights and Company News
6 month growth
8%1 year growth
8%2 year growth
8%Haemonetics (HAE) stock jumps 16% as CSL Plasma commits to full U.S. Equipment deployment. Key highlights. Table of Contents * Shares of Haemonetics jumped nearly 16% following CSL Plasma's commitment to deploy NexSys devices nationwide. * The plasma collection giant aims to finish equipment installations at over 300 U.S. facilities by the end of 2027. * BTIG analysts lifted their price target to $130, while Citi previously upgraded the stock to Buy. * Recent quarterly results showed $339.38 million in revenue and diluted earnings of $0.72 per share. * Market participants anticipate November 5 earnings release for updates on CSL partnership revenue projections. Shares of Haemonetics (HAE) climbed 15.96% on Thursday, October 8, 2026, reaching approximately $118 during morning hours from the prior close of $101.71. The rally followed CSL Plasma's disclosure of plans to deploy the medical device company's plasma collection technology throughout its entire U.S. footprint. CSL Plasma commits to comprehensive U.S. Deployment. CSL Plasma informed Haemonetics of its intention to install NexSys PCS devices equipped with Persona PLUS technology across every operational U.S. plasma donation center. The company established December 2027 as the completion target for this transition, affecting a network spanning more than 300 locations. This commitment builds upon an August supply agreement granting CSL flexibility to purchase Haemonetics equipment without binding minimum order quantities. The arrangement permits CSL to source from other suppliers, and specific implementation schedules await final confirmation between the partners. Earlier in the week, European healthcare stocks gained, supported in part by positive clinical trial developments. Wall street elevates Haemonetics (HAE) price projections. BTIG analysts increased their Haemonetics price objective from $110 to $130 on Thursday, maintaining their Buy recommendation. The previous month saw Citi shift its stance from Neutral to Buy, simultaneously raising its target from $92 to $123. These revisions arrived several weeks apart. Citi's analysis suggested that every 10% recovery in CSL-related business could contribute an additional $0.13 to annual earnings per share. Independent analyst estimates have placed potential annual sales from a complete CSL transition between $183 million and $223 million, though Haemonetics has issued no official guidance on these projections. Latest financial performance and Vivasure progress. The company's June quarter delivered $339.38 million in total revenue alongside $0.72 in diluted earnings per share. Top-line growth measured 5.6% year-over-year. Free cash flow generation totaled approximately $39.1 million for the period. Meanwhile, U.S. stock indexes set records during the same week, though increasing bond yields created headwinds for select healthcare equities. Haemonetics advanced its collaboration with Vivasure Medical through a $6.1 million milestone payment to Orchestra BioMed, bringing cumulative consideration to $11 million. The partnership structure allows for an additional $10 million in contingent payments tied to specific Vivasure revenue achievements. Market valuation and upcoming earnings release. The medical device manufacturer holds roughly $1.17 billion in long-term debt and traded near 50 times trailing earnings during Thursday's surge. This valuation multiple drew increased scrutiny following the day's price advance. A recent retail investor survey revealed unusually elevated equity allocations across the broader market. Haemonetics has maintained its fiscal 2027 outlook without revision, citing uncertainty around deployment timelines and order patterns. Management scheduled its second-quarter earnings announcement for November 5, when executives plan to provide clarity on anticipated revenue contributions from the expanded CSL relationship. Limited Time Offer Get 3 free stock ebooks. Discover top-performing stocks in AI, Crypto, and Technology with expert analysis. * Top 10 AI Stocks - Leading AI companies * Top 10 Crypto Stocks - Blockchain leaders * Top 10 Tech Stocks - Tech giants
Haemonetics shares jumped 12% after the company announced CSL now expects to move all of its current US plasma collection centres to Haemonetics' NexSys devices by the end of 2027. The deal, first disclosed in August, was initially limited to only a portion of CSL's US centres with no timeline. The expanded agreement is significant because losing CSL previously flattened Haemonetics' growth. In fiscal 2026, the company's organic revenue growth was just 1.1%, compared to 9.5% excluding lost CSL sales. Following the surge, Haemonetics trades at approximately 21 times forward earnings, above its five-year average of 19.1 times. The deal is non-exclusive with no minimum purchase requirements, meaning CSL can still modify scope and timing. Management plans to provide further details during its November earnings call.
Haemonetics reported Q2 revenues of $339.4 million, up 5.6% year-on-year and exceeding analyst expectations by 2.8%. The medical devices company, which specialises in blood collection and processing equipment, delivered a strong quarter with beats on both organic revenue and earnings per share estimates. The company's shares have risen 29.5% since the earnings announcement and currently trade at $108.25. Across the medical devices and supplies specialty sector, the seven tracked companies reported robust Q2 results. As a group, revenues beat analyst consensus estimates by 2.1%, with share prices averaging gains of 5.6% following earnings releases. The medical devices industry benefits from recurring revenue streams but faces ongoing pricing pressures from healthcare systems and insurers focused on cost efficiency.
Haemonetics reported second-quarter results that beat Wall Street expectations, with revenue of $339.4 million versus analyst estimates of $330.2 million and adjusted earnings per share of $1.14 versus estimates of $1.08. The medical technology company's performance was driven by strong execution across its business lines, particularly in Plasma and Interventional Technologies. New product launches including Persona PLUS and VASCADE MVP XL drove adoption and utilisation. CEO Christopher Simon said all three core platforms contributed to the quarter's results, demonstrating the breadth of the business. Organic revenue rose 5.9% year on year, whilst operating margin remained steady at 16.9%. During the earnings call, analysts questioned management on topics including market share gains in Interventional Technologies, gross margin progression, Persona PLUS adoption timing, and capital equipment budgeting trends.
Haemonetics (HAE) projected to announce quarterly earnings on Thursday. July 30, 2026 Key points. * Haemonetics is expected to report Q1 fiscal 2027 results before the market opens on August 6, 2026. Analysts project earnings of $1.07 per share on $327.9 million in revenue, while full-year guidance is $5.258-$5.307 EPS. * In its latest quarter, Haemonetics earned $1.29 per share, exceeding estimates by $0.01, and generated $346.35 million in revenue - up 4.8% year over year and above consensus. * The stock recently rose 3.7% to $85.63, near its 52-week high, while analysts maintain a "Moderate Buy" consensus with an average price target of $78.89. Institutional investors own approximately 99.67% of shares. * Five stocks we like better than Haemonetics. Haemonetics (NYSE:HAE - Get Free Report) is projected to release its Q1 2027 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of $1.07 per share and revenue of $327.8930 million for the quarter. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Parties may visit the the company's upcoming Q1 2027 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET. Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share for the quarter, beating analysts' consensus estimates of $1.28 by $0.01. The firm had revenue of $346.35 million for the quarter, compared to analyst estimates of $336.83 million. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. Haemonetics's quarterly revenue was up 4.8% on a year-over-year basis. During the same period last year, the firm posted $1.24 EPS. On average, analysts expect Haemonetics to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year. Haemonetics stock up 3.7%. Shares of Haemonetics stock opened at $85.63 on Thursday. Haemonetics has a one year low of $47.31 and a one year high of $87.32. The company has a market cap of $3.89 billion, a P/E ratio of 42.39, a PEG ratio of 1.66 and a beta of 0.52. The company has a debt-to-equity ratio of 1.53, a quick ratio of 1.87 and a current ratio of 2.95. The firm has a fifty day moving average of $74.25 and a two-hundred day moving average of $66.05. Analyst Ratings changes. Several research firms recently issued reports on HAE. Robert W. Baird set a $67.00 price target on shares of Haemonetics in a report on Friday, May 8th. Citigroup reaffirmed a "buy" rating on shares of Haemonetics in a report on Wednesday. Bank of America upgraded Haemonetics from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $72.00 to $80.00 in a research report on Friday, May 22nd. Weiss Ratings raised Haemonetics from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, June 25th. Finally, JPMorgan Chase & Co. reduced their price target on Haemonetics from $74.00 to $62.00 and set a "neutral" rating for the company in a report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, Haemonetics currently has a consensus rating of "Moderate Buy" and an average price target of $78.89. Discover more Self-Help & Motivational Financial News Institutional trading of Haemonetics. A number of institutional investors have recently added to or reduced their stakes in the stock. Kemnay Advisory Services Inc. acquired a new position in Haemonetics during the fourth quarter worth about $26,000. EverSource Wealth Advisors LLC lifted its position in shares of Haemonetics by 2,640.0% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier's stock valued at $31,000 after acquiring an additional 396 shares during the period. Kestra Advisory Services LLC acquired a new stake in shares of Haemonetics during the 4th quarter valued at approximately $34,000. UMB Bank n.a. boosted its stake in shares of Haemonetics by 110.9% during the 4th quarter. UMB Bank n.a. now owns 582 shares of the medical instruments supplier's stock worth $47,000 after acquiring an additional 306 shares in the last quarter. Finally, Parallel Advisors LLC boosted its stake in shares of Haemonetics by 172.9% during the 4th quarter. Parallel Advisors LLC now owns 625 shares of the medical instruments supplier's stock worth $50,000 after acquiring an additional 396 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock. About Haemonetics. Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company's offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management. The company's product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Haemonetics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list. While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain - combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.